このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

TherapeuticsMD 将来の成長

Future 基準チェック /16

TherapeuticsMDは、30.1%と18.5%でそれぞれ年率30.1%で利益と収益が成長すると予測される一方、EPSはgrowで35.7%年率。

主要情報

30.1%

収益成長率

35.7%

EPS成長率

Pharmaceuticals 収益成長	21.5%
収益成長率	18.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:29TA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2024	174	-7	N/A	N/A	1
12/31/2023	150	-29	N/A	N/A	1
12/31/2022	112	28	N/A	N/A	1
6/30/2022	92	-27	-125	-123	N/A
3/31/2022	86	-182	-136	-134	N/A
12/31/2021	87	-172	-145	-143	N/A
9/30/2021	91	-172	-135	-133	N/A
6/30/2021	85	-157	-131	-129	N/A
3/31/2021	72	-166	-160	-159	N/A
12/31/2020	65	-184	-161	-159	N/A
9/30/2020	58	-191	-202	-180	N/A
6/30/2020	63	-190	-195	-172	N/A
3/31/2020	58	-193	-190	-167	N/A
12/31/2019	50	-176	-190	-166	N/A
9/30/2019	39	-166	-147	-143	N/A
6/30/2019	19	-170	-174	-151	N/A
3/31/2019	16	-148	-147	-125	N/A
12/31/2018	16	-133	-128	-107	N/A
9/30/2018	15	-115	-121	-99	N/A
6/30/2018	16	-94	-83	-82	N/A
3/31/2018	17	-80	-76	-75	N/A
12/31/2017	17	-77	-77	-76	N/A
9/30/2017	17	-78	-72	-71	N/A
6/30/2017	18	-89	-74	-73	N/A
3/31/2017	18	-90	-71	-70	N/A
12/31/2016	19	-90	-70	-69	N/A
9/30/2016	20	-85	-71	-70	N/A
6/30/2016	20	-79	-71	-70	N/A
3/31/2016	21	-85	N/A	-79	N/A
12/31/2015	20	-85	N/A	-79	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 29TA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 29TA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 29TA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 29TAの収益 ( 18.5% ) German市場 ( 5.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: 29TAの収益 ( 18.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 29TAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

TherapeuticsMD 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

No longer forecast to breakeven

Recent updates

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021)

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought €510k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought €619k worth of stock

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

Revenue beats expectations

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high: €1.31

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

New 90-day low: €0.94

New 90-day low: €1.03

Revenue beats expectations

Third quarter 2020 earnings released: US$0.12 loss per share

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

New 90-day low: €1.06

TherapeuticsMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA

First half earnings released

TherapeuticsMD, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - €1.92

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from S&P Pharmaceuticals Select Industry Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘